JPH0244319B2 - - Google Patents
Info
- Publication number
- JPH0244319B2 JPH0244319B2 JP57031555A JP3155582A JPH0244319B2 JP H0244319 B2 JPH0244319 B2 JP H0244319B2 JP 57031555 A JP57031555 A JP 57031555A JP 3155582 A JP3155582 A JP 3155582A JP H0244319 B2 JPH0244319 B2 JP H0244319B2
- Authority
- JP
- Japan
- Prior art keywords
- complex
- maleic anhydride
- neocarzinostatin
- ncs
- sma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- QZGIWPZCWHMVQL-UIYAJPBUSA-N neocarzinostatin chromophore Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1O[C@@H]1C/2=C/C#C[C@H]3O[C@@]3([C@@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(O)C=CC2=C(C)C=C(OC)C=C12 QZGIWPZCWHMVQL-UIYAJPBUSA-N 0.000 claims description 38
- 101710204212 Neocarzinostatin Proteins 0.000 claims description 34
- 229950009268 zinostatin Drugs 0.000 claims description 34
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical group O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 claims description 14
- 229920001577 copolymer Polymers 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 229920000147 Styrene maleic anhydride Polymers 0.000 description 33
- PYSRRFNXTXNWCD-UHFFFAOYSA-N 3-(2-phenylethenyl)furan-2,5-dione Chemical compound O=C1OC(=O)C(C=CC=2C=CC=CC=2)=C1 PYSRRFNXTXNWCD-UHFFFAOYSA-N 0.000 description 16
- 206010028980 Neoplasm Diseases 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 13
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 12
- 201000011510 cancer Diseases 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 238000000862 absorption spectrum Methods 0.000 description 8
- 239000002246 antineoplastic agent Substances 0.000 description 7
- 229940041181 antineoplastic drug Drugs 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 239000011976 maleic acid Substances 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 5
- 238000000921 elemental analysis Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 210000004324 lymphatic system Anatomy 0.000 description 4
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 4
- HFPZCAJZSCWRBC-UHFFFAOYSA-N p-cymene Chemical compound CC(C)C1=CC=C(C)C=C1 HFPZCAJZSCWRBC-UHFFFAOYSA-N 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 2
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 2
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- 125000005907 alkyl ester group Chemical group 0.000 description 2
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 2
- 239000001099 ammonium carbonate Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 238000011026 diafiltration Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 229920000298 Cellophane Polymers 0.000 description 1
- 235000008753 Papaver somniferum Nutrition 0.000 description 1
- 240000001090 Papaver somniferum Species 0.000 description 1
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 241000186991 Streptomyces carzinostaticus Species 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 229920005603 alternating copolymer Polymers 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- XIXADJRWDQXREU-UHFFFAOYSA-M lithium acetate Chemical compound [Li+].CC([O-])=O XIXADJRWDQXREU-UHFFFAOYSA-M 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP57031555A JPS58149903A (ja) | 1982-02-27 | 1982-02-27 | ネオカルチノスタチン複合体の製造法 |
| EP83301027A EP0087957B1 (en) | 1982-02-27 | 1983-02-25 | Neocarzinostatin complexes, a method for producing the same, and an antitumor agent containing said complexes as an active component |
| AT83301027T ATE23863T1 (de) | 1982-02-27 | 1983-02-25 | Neocarzinostatinkomplexe, verfahren zu ihrer herstellung und antitumormittel, das diese komplexe als aktive komponente enhaelt. |
| DE8383301027T DE3367921D1 (en) | 1982-02-27 | 1983-02-25 | Neocarzinostatin complexes, a method for producing the same, and an antitumor agent containing said complexes as an active component |
| CA000422497A CA1214458A (en) | 1982-02-27 | 1983-02-28 | Neocarzinostatin complexes, a method for producing the same, and an antitumor agent containing said complexes as an active component |
| US06/730,823 US4732933A (en) | 1982-02-27 | 1985-05-06 | Neocarzinostatin complexes, a method for producing the same, and an antitumor agent containing said complexes as an active component |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP57031555A JPS58149903A (ja) | 1982-02-27 | 1982-02-27 | ネオカルチノスタチン複合体の製造法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS58149903A JPS58149903A (ja) | 1983-09-06 |
| JPH0244319B2 true JPH0244319B2 (es) | 1990-10-03 |
Family
ID=12334426
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP57031555A Granted JPS58149903A (ja) | 1982-02-27 | 1982-02-27 | ネオカルチノスタチン複合体の製造法 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS58149903A (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59139396A (ja) * | 1983-01-31 | 1984-08-10 | Kuraray Co Ltd | ネオカルチノスタチン複合体の製造方法 |
| JPS63211238A (ja) * | 1987-02-27 | 1988-09-02 | Masayasu Inoue | 抗潰瘍剤 |
| JP2556865B2 (ja) * | 1986-09-19 | 1996-11-27 | 山之内製薬株式会社 | ネオカルチノスタチン誘導体の非注射投与用組成物 |
| GB0123232D0 (en) | 2001-09-26 | 2001-11-21 | Smith & Nephew | Polymers |
| PT1627645T (pt) * | 2003-05-26 | 2017-11-23 | Maeda Hiroshi | Agente antitumoral e processo para a sua produção |
| WO2006112361A1 (ja) * | 2005-04-18 | 2006-10-26 | Hiroshi Maeda | 高分子型癌治療用医薬およびその製造方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS53117095A (en) * | 1977-03-24 | 1978-10-13 | Hiroshi Maeda | Neocarcinostachin derivative and producing process thereof |
-
1982
- 1982-02-27 JP JP57031555A patent/JPS58149903A/ja active Granted
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS53117095A (en) * | 1977-03-24 | 1978-10-13 | Hiroshi Maeda | Neocarcinostachin derivative and producing process thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS58149903A (ja) | 1983-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4745664B2 (ja) | カンプトテシン類の高分子誘導体 | |
| JP5369137B2 (ja) | 新規ブロック共重合体、ミセル調製物及びそれを有効成分とする抗癌剤 | |
| RU2384593C2 (ru) | Таксаны, ковалентно связанные с гиалуроновой кислотой или производными гиалуроновой кислоты | |
| JP4272537B2 (ja) | Ｙ型分鎖親水性ポリマー誘導体、それらの調製方法、前記誘導体および薬剤分子の結合生成物、ならびに前記結合生成物を含む医薬組成物 | |
| JP4039466B2 (ja) | 新規アンスラサイクリン系化合物誘導体及びそれを含む医薬製剤 | |
| US5130126A (en) | Polymer-drug conjugate and a method of producing it | |
| JP4663233B2 (ja) | ベンジル脱離系を利用する高分子チオール結合プロドラッグ | |
| CN110591078B (zh) | 还原/pH双重响应性阿霉素前药的制备方法 | |
| JP2005513006A6 (ja) | ベンジル脱離系を利用する高分子チオール結合プロドラッグ | |
| EP4066860A1 (en) | Polyethylene glycol conjugated drug, and preparation method therefor and use thereof | |
| EP0087957B1 (en) | Neocarzinostatin complexes, a method for producing the same, and an antitumor agent containing said complexes as an active component | |
| CN108026271A (zh) | 6配位铂络合物的高分子偶联物 | |
| JPH0244319B2 (es) | ||
| EP0354836A1 (fr) | Polymères iodés à squelette dextrane, leurs procédés de préparation et leurs applications comme produits de contraste | |
| KR100348380B1 (ko) | 항종양미토크산트론중합체조성물 | |
| JPH0123480B2 (es) | ||
| JPH0278699A (ja) | ベンゾイルウレア系化合物・アルブミン複合体 | |
| EP0452179A2 (en) | Polymer-combined drug for gastric treatment and a method for producing the drug | |
| EP4190361A1 (en) | Polyethylene glycol conjugate drug, and preparation method therfor and use thereof | |
| JPS6330886B2 (es) | ||
| CN111346234B (zh) | 去铁胺-八臂星型聚乙二醇结合物及其应用 | |
| CN1206257C (zh) | 亲水性聚合物－水飞蓟提取物的结合物以及包含该结合物的药物组合物 | |
| JPH05132431A (ja) | 高分子化薬剤およびその製造法 | |
| RU2805370C1 (ru) | Лекарственное средство, представляющее собой конъюгат с полиэтиленгликолем, способ его получения и его применение | |
| CN114948926A (zh) | 一种线粒体靶向的卡巴他赛药物前体及其制备方法和应用 |